Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K. Drug Regulator Follows U.S. FDA; Seeks Closer Ties With India's DCGI

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Following U.S. FDA's moves to work closely with the Drug Controller General of India - the Indian drug regulator - the United Kingdom's Medicines and Healthcare products Regulatory Agency has held discussions with the Indian health department officials to build closer relationships

You may also be interested in...



U.S. FDA Mulls Joint Action With India’s DCGI For Closer Scrutiny Of Clinical Research Organizations

MUMBAI - After setting up a full-fledged India office, U.S. FDA is now planning to initiate its Bioresearch Monitoring Program aimed at comprehensive on-site inspections and data audits designed to monitor all aspects of U.S. FDA-regulated research

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel